Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

957 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors.
Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, van Zoelen EJ, Weber RF, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW. Looijenga LH, et al. Among authors: bokemeyer c. Cancer Res. 2003 May 1;63(9):2244-50. Cancer Res. 2003. PMID: 12727846
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).
Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C. Kollmannsberger C, et al. Among authors: bokemeyer c. Ann Oncol. 2006 Jun;17(6):1007-13. doi: 10.1093/annonc/mdl042. Epub 2006 Mar 13. Ann Oncol. 2006. PMID: 16533873 Free article. Clinical Trial.
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.
Balabanov S, Gontarewicz A, Ziegler P, Hartmann U, Kammer W, Copland M, Brassat U, Priemer M, Hauber I, Wilhelm T, Schwarz G, Kanz L, Bokemeyer C, Hauber J, Holyoake TL, Nordheim A, Brümmendorf TH. Balabanov S, et al. Among authors: bokemeyer c. Blood. 2007 Feb 15;109(4):1701-11. doi: 10.1182/blood-2005-03-037648. Epub 2006 Sep 28. Blood. 2007. PMID: 17008552 Free article.
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH. Gontarewicz A, et al. Among authors: bokemeyer c. Blood. 2008 Apr 15;111(8):4355-64. doi: 10.1182/blood-2007-09-113175. Epub 2008 Feb 11. Blood. 2008. PMID: 18268096 Free article.
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH. Gontarewicz A, et al. Among authors: bokemeyer c. Leuk Res. 2008 Dec;32(12):1857-65. doi: 10.1016/j.leukres.2008.04.012. Epub 2008 Jun 2. Leuk Res. 2008. PMID: 18514829
HER-2 amplification is highly homogenous in gastric cancer.
Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G. Marx AH, et al. Among authors: bokemeyer c. Hum Pathol. 2009 Jun;40(6):769-77. doi: 10.1016/j.humpath.2008.11.014. Epub 2009 Mar 9. Hum Pathol. 2009. PMID: 19269014
HER-2/neu analysis in breast cancer bone metastases.
Zustin J, Boddin K, Tsourlakis MC, Burandt E, Mirlacher M, Jaenicke F, Izbicki J, Ruether W, Rueger JM, Bokemeyer C, Simon R, Sauter G. Zustin J, et al. Among authors: bokemeyer c. J Clin Pathol. 2009 Jun;62(6):542-6. doi: 10.1136/jcp.2008.059717. J Clin Pathol. 2009. PMID: 19474354
Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal AT, Brüchmann M, Zustin J, Isbarn H, Hellwinkel OJ, Köllermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brümmendorf TH, Izbicki JR, Yekebas E, Fisch M, Huland H, Graefen M, Schlomm T. El Gammal AT, et al. Among authors: bokemeyer c. Clin Cancer Res. 2010 Jan 1;16(1):56-64. doi: 10.1158/1078-0432.CCR-09-1423. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028754
957 results